Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2018 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.9%

Alnylam Pharmaceuticals reported a loss that was slightly better than expected, which led to a modest decline in the stock price. The lack of revenue figures and guidance may have contributed to investor caution. Overall, the company is facing challenges but remains committed to its long-term goals.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.22	N/A	+7.63%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current market environment. They remain focused on their strategic initiatives while navigating short-term challenges.

Management highlighted ongoing challenges in revenue generation.

They emphasized a focus on long-term strategies despite current losses.

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.9%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.9%

Key numbers

Management commentary